Wall Street analysts forecast that Assembly Biosciences, Inc. (NASDAQ:ASMB) will post earnings of ($0.55) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.53). Assembly Biosciences posted earnings of ($0.09) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 511.1%. The firm is expected to announce its next quarterly earnings results on Thursday, November 4th.
On average, analysts expect that Assembly Biosciences will report full-year earnings of ($2.29) per share for the current fiscal year, with EPS estimates ranging from ($2.39) to ($2.16). For the next financial year, analysts forecast that the firm will post earnings of ($2.19) per share, with EPS estimates ranging from ($3.24) to ($1.48). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.11. Assembly Biosciences had a negative return on equity of 37.80% and a negative net margin of 78.57%.
NASDAQ:ASMB opened at $3.23 on Wednesday. The firm has a market capitalization of $145.26 million, a price-to-earnings ratio of -1.32 and a beta of 0.34. Assembly Biosciences has a twelve month low of $3.09 and a twelve month high of $18.30. The stock’s 50 day moving average price is $3.49 and its two-hundred day moving average price is $3.98.
In related news, CEO John G. Mchutchison sold 12,156 shares of the business’s stock in a transaction on Monday, August 9th. The stock was sold at an average price of $3.60, for a total value of $43,761.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.90% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG3 Management LLC bought a new stake in Assembly Biosciences in the 2nd quarter valued at $39,000. Royal Bank of Canada raised its holdings in Assembly Biosciences by 185.4% in the 2nd quarter. Royal Bank of Canada now owns 10,319 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 6,703 shares in the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new position in Assembly Biosciences in the 2nd quarter valued at $42,000. New York Life Investments Alternatives acquired a new position in Assembly Biosciences in the 2nd quarter valued at $44,000. Finally, Bridgefront Capital LLC acquired a new position in Assembly Biosciences in the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 65.08% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate.
Recommended Story: What sectors are represented in the Hang Seng index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.